CLASS II Drug recall · Reported 18 Apr 2018 · FDA Enforcement Report

Conzerol zero molluscum contagiosum, Topical Cream recalled

Elroselabs is recalling Conzerol zero molluscum contagiosum, Topical Cream, distributed nationwide in the US. The recall was initiated on 28 Mar 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesAll product within expiry
Quantity recalledUnknown

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0621-2018
FDA event ID
79606
Recalling firm
Elroselabs, Sanford, FL
Classification
Class II
Status
Terminated
Recall initiated
28 Mar 2018
FDA classified
6 Apr 2018
Reported
18 Apr 2018
Type
Voluntary: Firm initiated
Customers notified by
Letter

Timeline

28 Mar 2018Recall initiated by company
6 Apr 2018Classified by FDA+9 days
18 Apr 2018Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

cGMP Deviations

Product as listed by the FDA

Conzerol zero molluscum contagiosum, Topical Cream, Net weight 0.78 (22g), Elrose Labs, Sanford Fl 32771 USA --- NDC 70223-001-06

Where it was distributed

Nationwide.

Nationwide

Questions about this recall

Is Conzerol zero molluscum contagiosum, Topical Cream recalled?

Yes. Elroselabs recalled Conzerol zero molluscum contagiosum, Topical Cream on 28 Mar 2018. The recall is Class II and its status is Terminated. Recall number D-0621-2018.

Why was it recalled?

cGMP Deviations

Which lots are affected?

All product within expiry

Where was it sold?

Nationwide.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Elroselabs

All 3